Content Marketing in Pharma: How to Turn Production Capabilities into Reputational
The days of "silence" in B2B pharma are over. A decade ago, manufacturing plants could operate quietly for years, relying solely on the personal networks of their commercial directors. Today, such a strategy is a brake on growth.
Obesity Pill Battle: Lilly’s Chemistry vs. Novo’s Peptides
2026 marks not just the arrival of new therapies,...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
FEFU to Launch Russia’s First University-Based GMP Site for Biologics
Far Eastern Federal University (FEFU) has announced plans to establish a comprehensive infrastructure for the development and commercialization of biotech products.
FMBA Files for Registration of “Allergarda,” a Recombinant Vaccine for Birch Pollen Allergy
The vaccine is currently in Phase III clinical trials, evaluating its efficacy against a placebo in patients with allergic rhinitis.
Content Marketing in Pharma: How to Turn Production Capabilities into Reputational
The days of "silence" in B2B pharma are over. A decade ago, manufacturing plants could operate quietly for years, relying solely on the personal networks of their commercial directors. Today, such a strategy is a brake on growth.
Obesity Pill Battle: Lilly’s Chemistry vs. Novo’s Peptides
2026 marks not just the arrival of new therapies,...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
FEFU to Launch Russia’s First University-Based GMP Site for Biologics
Far Eastern Federal University (FEFU) has announced plans to establish a comprehensive infrastructure for the development and commercialization of biotech products.
FMBA Files for Registration of “Allergarda,” a Recombinant Vaccine for Birch Pollen Allergy
The vaccine is currently in Phase III clinical trials, evaluating its efficacy against a placebo in patients with allergic rhinitis.
Content Marketing in Pharma: How to Turn Production Capabilities into Reputational
The days of "silence" in B2B pharma are over. A decade ago, manufacturing plants could operate quietly for years, relying solely on the personal networks of their commercial directors. Today, such a strategy is a brake on growth.
Obesity Pill Battle: Lilly’s Chemistry vs. Novo’s Peptides
2026 marks not just the arrival of new therapies,...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
FEFU to Launch Russia’s First University-Based GMP Site for Biologics
Far Eastern Federal University (FEFU) has announced plans to establish a comprehensive infrastructure for the development and commercialization of biotech products.
FMBA Files for Registration of “Allergarda,” a Recombinant Vaccine for Birch Pollen Allergy
The vaccine is currently in Phase III clinical trials, evaluating its efficacy against a placebo in patients with allergic rhinitis.
Content Marketing in Pharma: How to Turn Production Capabilities into Reputational
The days of "silence" in B2B pharma are over. A decade ago, manufacturing plants could operate quietly for years, relying solely on the personal networks of their commercial directors. Today, such a strategy is a brake on growth.
Obesity Pill Battle: Lilly’s Chemistry vs. Novo’s Peptides
2026 marks not just the arrival of new therapies,...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
FEFU to Launch Russia’s First University-Based GMP Site for Biologics
Far Eastern Federal University (FEFU) has announced plans to establish a comprehensive infrastructure for the development and commercialization of biotech products.
FMBA Files for Registration of “Allergarda,” a Recombinant Vaccine for Birch Pollen Allergy
The vaccine is currently in Phase III clinical trials, evaluating its efficacy against a placebo in patients with allergic rhinitis.
Content Marketing in Pharma: How to Turn Production Capabilities into Reputational
The days of "silence" in B2B pharma are over. A decade ago, manufacturing plants could operate quietly for years, relying solely on the personal networks of their commercial directors. Today, such a strategy is a brake on growth.
Obesity Pill Battle: Lilly’s Chemistry vs. Novo’s Peptides
2026 marks not just the arrival of new therapies,...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
FEFU to Launch Russia’s First University-Based GMP Site for Biologics
Far Eastern Federal University (FEFU) has announced plans to establish a comprehensive infrastructure for the development and commercialization of biotech products.
FMBA Files for Registration of “Allergarda,” a Recombinant Vaccine for Birch Pollen Allergy
The vaccine is currently in Phase III clinical trials, evaluating its efficacy against a placebo in patients with allergic rhinitis.
Content Marketing in Pharma: How to Turn Production Capabilities into Reputational
The days of "silence" in B2B pharma are over. A decade ago, manufacturing plants could operate quietly for years, relying solely on the personal networks of their commercial directors. Today, such a strategy is a brake on growth.
Obesity Pill Battle: Lilly’s Chemistry vs. Novo’s Peptides
2026 marks not just the arrival of new therapies,...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
FEFU to Launch Russia’s First University-Based GMP Site for Biologics
Far Eastern Federal University (FEFU) has announced plans to establish a comprehensive infrastructure for the development and commercialization of biotech products.
FMBA Files for Registration of “Allergarda,” a Recombinant Vaccine for Birch Pollen Allergy
The vaccine is currently in Phase III clinical trials, evaluating its efficacy against a placebo in patients with allergic rhinitis.
Content Marketing in Pharma: How to Turn Production Capabilities into Reputational
The days of "silence" in B2B pharma are over. A decade ago, manufacturing plants could operate quietly for years, relying solely on the personal networks of their commercial directors. Today, such a strategy is a brake on growth.
Obesity Pill Battle: Lilly’s Chemistry vs. Novo’s Peptides
2026 marks not just the arrival of new therapies,...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
FEFU to Launch Russia’s First University-Based GMP Site for Biologics
Far Eastern Federal University (FEFU) has announced plans to establish a comprehensive infrastructure for the development and commercialization of biotech products.
FMBA Files for Registration of “Allergarda,” a Recombinant Vaccine for Birch Pollen Allergy
The vaccine is currently in Phase III clinical trials, evaluating its efficacy against a placebo in patients with allergic rhinitis.
Content Marketing in Pharma: How to Turn Production Capabilities into Reputational
The days of "silence" in B2B pharma are over. A decade ago, manufacturing plants could operate quietly for years, relying solely on the personal networks of their commercial directors. Today, such a strategy is a brake on growth.
Obesity Pill Battle: Lilly’s Chemistry vs. Novo’s Peptides
2026 marks not just the arrival of new therapies,...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
FEFU to Launch Russia’s First University-Based GMP Site for Biologics
Far Eastern Federal University (FEFU) has announced plans to establish a comprehensive infrastructure for the development and commercialization of biotech products.
FMBA Files for Registration of “Allergarda,” a Recombinant Vaccine for Birch Pollen Allergy
The vaccine is currently in Phase III clinical trials, evaluating its efficacy against a placebo in patients with allergic rhinitis.
PHARMPROM is a premier digital resource for the pharmaceutical sector, combining breaking news, deep insights, and key market events. We cover the entire product lifecycle—from R&D and manufacturing to distribution—in strict accordance with Good Pharmaceutical Practices (GxP).
Disclaimer All content on pharmprom.net is for informational purposes only and does not constitute medical advice. The materials are intended exclusively for industry professionals and are not addressed to the general public.
Headlines
Content Marketing in Pharma: How to Turn Production Capabilities into Reputational
The days of "silence" in B2B pharma are over. A decade ago, manufacturing plants could operate quietly for years, relying solely on the personal networks of their commercial directors. Today, such a strategy is a brake on growth.
Obesity Pill Battle: Lilly’s Chemistry vs. Novo’s Peptides
2026 marks not just the arrival of new therapies,...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
FEFU to Launch Russia’s First University-Based GMP Site for Biologics
Far Eastern Federal University (FEFU) has announced plans to establish a comprehensive infrastructure for the development and commercialization of biotech products.
Newsletter
Get important news delivered directly to your inbox and stay connected!
© PHARMPROM 2026